142 related articles for article (PubMed ID: 12191605)
1. Structure-based design of cyclin-dependent kinase inhibitors.
Davies TG; Pratt DJ; Endicott JA; Johnson LN; Noble ME
Pharmacol Ther; 2002; 93(2-3):125-33. PubMed ID: 12191605
[TBL] [Abstract][Full Text] [Related]
2. Critical role for the 310 helix region of p57(Kip2) in cyclin-dependent kinase 2 inhibition and growth suppression.
Hashimoto Y; Kohri K; Kaneko Y; Morisaki H; Kato T; Ikeda K; Nakanishi M
J Biol Chem; 1998 Jun; 273(26):16544-50. PubMed ID: 9632724
[TBL] [Abstract][Full Text] [Related]
3. Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2.
Johnson LN; De Moliner E; Brown NR; Song H; Barford D; Endicott JA; Noble ME
Pharmacol Ther; 2002; 93(2-3):113-24. PubMed ID: 12191604
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor.
Davies TG; Bentley J; Arris CE; Boyle FT; Curtin NJ; Endicott JA; Gibson AE; Golding BT; Griffin RJ; Hardcastle IR; Jewsbury P; Johnson LN; Mesguiche V; Newell DR; Noble ME; Tucker JA; Wang L; Whitfield HJ
Nat Struct Biol; 2002 Oct; 9(10):745-9. PubMed ID: 12244298
[TBL] [Abstract][Full Text] [Related]
5. Formation of p27-CDK complexes during the human mitotic cell cycle.
Soos TJ; Kiyokawa H; Yan JS; Rubin MS; Giordano A; DeBlasio A; Bottega S; Wong B; Mendelsohn J; Koff A
Cell Growth Differ; 1996 Feb; 7(2):135-46. PubMed ID: 8822197
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
De Azevedo WF; Leclerc S; Meijer L; Havlicek L; Strnad M; Kim SH
Eur J Biochem; 1997 Jan; 243(1-2):518-26. PubMed ID: 9030780
[TBL] [Abstract][Full Text] [Related]
7. A new pathway for mitogen-dependent cdk2 regulation uncovered in p27(Kip1)-deficient cells.
Coats S; Whyte P; Fero ML; Lacy S; Chung G; Randel E; Firpo E; Roberts JM
Curr Biol; 1999 Feb; 9(4):163-73. PubMed ID: 10074425
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex.
Russo AA; Jeffrey PD; Patten AK; Massagué J; Pavletich NP
Nature; 1996 Jul; 382(6589):325-31. PubMed ID: 8684460
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
10. Nuclear accumulation of cyclin E/Cdk2 triggers a concentration-dependent switch for the destruction of p27Xic1.
Swanson C; Ross J; Jackson PK
Proc Natl Acad Sci U S A; 2000 Jul; 97(14):7796-801. PubMed ID: 10884410
[TBL] [Abstract][Full Text] [Related]
11. The cell cycle inhibitor p21CIP is phosphorylated by cyclin A-CDK2 complexes.
Jaumot M; Estañol JM; Casanovas O; Graña X; Agell N; Bachs O
Biochem Biophys Res Commun; 1997 Dec; 241(2):434-8. PubMed ID: 9425288
[TBL] [Abstract][Full Text] [Related]
12. X-ray crystallographic studies of CDK2, a basis for cyclin-dependent kinase inhibitor design in anti-cancer drug research.
Furet P
Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):15-23. PubMed ID: 12678911
[TBL] [Abstract][Full Text] [Related]
13. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.
Barvian M; Boschelli DH; Cossrow J; Dobrusin E; Fattaey A; Fritsch A; Fry D; Harvey P; Keller P; Garrett M; La F; Leopold W; McNamara D; Quin M; Trumpp-Kallmeyer S; Toogood P; Wu Z; Zhang E
J Med Chem; 2000 Nov; 43(24):4606-16. PubMed ID: 11101352
[TBL] [Abstract][Full Text] [Related]
14. Dependence of cyclin E-CDK2 kinase activity on cell anchorage.
Fang F; Orend G; Watanabe N; Hunter T; Ruoslahti E
Science; 1996 Jan; 271(5248):499-502. PubMed ID: 8560263
[TBL] [Abstract][Full Text] [Related]
15. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
Hirai H; Kawanishi N; Iwasawa Y
Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
[TBL] [Abstract][Full Text] [Related]
17. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells.
Orend G; Hunter T; Ruoslahti E
Oncogene; 1998 May; 16(20):2575-83. PubMed ID: 9632134
[TBL] [Abstract][Full Text] [Related]
18. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
Mettey Y; Gompel M; Thomas V; Garnier M; Leost M; Ceballos-Picot I; Noble M; Endicott J; Vierfond JM; Meijer L
J Med Chem; 2003 Jan; 46(2):222-36. PubMed ID: 12519061
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
20. Cyclin E-CDK2 is a regulator of p27Kip1.
Sheaff RJ; Groudine M; Gordon M; Roberts JM; Clurman BE
Genes Dev; 1997 Jun; 11(11):1464-78. PubMed ID: 9192873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]